Skip to main content

Peer Review reports

From: Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial

Original Submission
1 Jun 2023 Submitted Original manuscript
11 Jul 2023 Reviewed Reviewer Report
15 Jul 2023 Reviewed Reviewer Report - Melvin L.K. Chua
15 Jul 2023 Reviewed Reviewer Report
22 Aug 2023 Author responded Author comments - Yu Fang
Resubmission - Version 2
22 Aug 2023 Submitted Manuscript version 2
24 Aug 2023 Reviewed Reviewer Report
2 Sep 2023 Reviewed Reviewer Report - Melvin L.K. Chua
8 Sep 2023 Reviewed Reviewer Report
23 Sep 2023 Author responded Author comments - Yu Fang
Resubmission - Version 3
23 Sep 2023 Submitted Manuscript version 3
28 Sep 2023 Reviewed Reviewer Report
19 Oct 2023 Author responded Author comments - Yu Fang
Resubmission - Version 4
19 Oct 2023 Submitted Manuscript version 4
26 Oct 2023 Author responded Author comments - Yu Fang
Resubmission - Version 5
26 Oct 2023 Submitted Manuscript version 5
Publishing
30 Oct 2023 Editorially accepted
7 Nov 2023 Article published 10.1186/s12916-023-03140-x

You can find further information about peer review here.

Back to article page